Author:
Chai Zheng,Zhang Peiyi,Fu Fang,Zhang Xueyun,Liu Ying,Hu Lihua,Li Xi
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA: Cancer J Clin 2008, 58: 71-96. 10.3322/CA.2007.0010
2. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H, Spyratos D: Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 2013, 5: S389-S396.
3. Zhang J-F, Wei F, Wang H-P, Li H-M, Qiu W, Ren P-K, Chen X-F, Huang Q: Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res 2010, 29: 52. 10.1186/1756-9966-29-52
4. Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK: Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol 2010, 84: 3835-3844. 10.1128/JVI.01553-09
5. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martinez-Sobrido L, Woo SL, Garcia-Sastre A: Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 2007, 67: 8285-8292. 10.1158/0008-5472.CAN-07-1025
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献